TIPE2 and asthma: Intranasal administration of crocetin (100 μM/day, for 9-10 weeks) in OVA-induced asthma in mice, reduced the number of Treg cells and the levels of Foxp3 and TIPE2, indicating treatment properties of crocetin in asthma (195).